gemcitabine hydrochloride

Chemical Name Gemcitabine Hydrochloride
Portland OR
SynonymCytidine, 2'-deoxy-2',2'-difluoro-, hydrochloride (1:1)
(CA INDEX NAME)
Chemical FormulaC9H11F2N3O4 · HCl
CAS Number122111-03-9
Section II.
Composition and Information on Ingredients
Toxicology Data
Chemical NameCAS Number Percent (%)TLV/PEL
Min. 98.0 Not available.Rat LD50 (intravenous) 236 mg/kg
Gemcitabine Hydrochloride122111-03-9
(HPLC,N)Mouse LD50 (intravenous) 500
mg/kg
Section III. Hazards Identification

Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the
Acute Health Effects
eye is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening, or,
occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
CARCINOGENIC EFFECTS : Not available.
Chronic Health Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Reproductive effects.
Mouse TDLo Intravenous 15 mg/kg, female 6-15 days of pregnancy
Toxic Effects:
Maternal Effects - Parturition
Effects on Fertility - Post-implantation mortality
Effects on Fertility - Litter size
Mouse TDLo Intravenous 15 mg/kg, female 6-15 days of pregnancy
Toxic Effects:
Maternal Effects - Other effects
Effects on Embryo or Fetus - Fetotoxicity
Effects on Embryo or Fetus - Fetal death
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Section IV.
First Aid Measures
Eye ContactCheck for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Get medical attention.
Skin ContactIn case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
Inhalation
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Ingestion
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the toxic
material was ingested; the absence of such signs, however, is not conclusive.
Section V.
Fire and Explosion Data
Not available.
May be combustible at high temperature.Auto-Ignition
Flammability
Flash PointsFlammable LimitsNot available.
Not available.
These products are toxic carbon oxides (CO, CO2), nitrogen oxides (NO, NO2), halogenated compounds.
Combustion Products
WARNING: Highly toxic HCl gas is produced during combustion.
WARNING: Highly toxic HF gas is produced during combustion.
Fire Hazards
Not available.
Continued on Next Page
Gemcitabine Hydrochloride
Explosion HazardsRisks of explosion of the product in presence of mechanical impact: Not available.
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting MediaSMALL FIRE: Use DRY chemical powder.
LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
and Instructions
Consult with local fire authorities before attempting large scale fire-fighting operations.
Section VI.
Accidental Release Measures
Spill CleanupIrritating material. This material is a reproductive effector.
Use a shovel to put the material into a convenient waste disposal container. Consult federal, state, and/or local authorities for
Instructions
assistance on disposal.
Section VII. Handling and Storage

IRRITANT. REPRODUCTIVE EFFECTOR. Keep away from heat. Mechanical exhaust required. When not in use, tightly
Handling and Storage
seal the container and store in a dry, cool place. Avoid excessive heat and light. Do not breathe dust.
Information
Always store away from incompatible compounds such as oxidizing agents.
Section VIII. Exposure Controls/Personal Protection

Engineering ControlsUse process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal ProtectionSplash goggles. Lab coat. Dust respirator. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a
specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Not available.
Exposure Limits
Section IX. Physical and Chemical Properties

Physical state @ 20°CSolid. (White crystalline powder.)SolubilitySoluble in hot water.
Not available.
Specific Gravity
Molecular Weight299.66Partition CoefficientNot available.
Boiling PointNot available.Not applicable.
Vapor Pressure
Melting Point287 to 292°C (548.6 to 557.6°F) (dec.)Vapor DensityNot available.
Not available.Not available.
Refractive IndexVolatility
Critical TemperatureNot available.OdorNot available.
Not available.Not available.
ViscosityTaste
Section X.
Stability and Reactivity Data
This material is stable if stored under proper conditions. (See Section VII for instructions)

Stability
Conditions of InstabilityAvoid excessive heat and light.
IncompatibilitiesReactive with oxidizing agents.
Section XI. Toxicological Information

RTECS NumberHA3840000
Eye Contact. Ingestion. Inhalation.
Routes of Exposure
Rat LD50 (intravenous) 236 mg/kg
Toxicity Data
Mouse LD50 (intravenous) 500 mg/kg
CARCINOGENIC EFFECTS : Not available.
Chronic Toxic Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Reproductive effects.
Mouse TDLo Intravenous 15 mg/kg, female 6-15 days of pregnancy
Toxic Effects:
Maternal Effects - Parturition
Effects on Fertility - Post-implantation mortality
Effects on Fertility - Litter size
Mouse TDLo Intravenous 15 mg/kg, female 6-15 days of pregnancy
Toxic Effects:
Maternal Effects - Other effects
Effects on Embryo or Fetus - Fetotoxicity
Effects on Embryo or Fetus - Fetal death
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Continued on Next Page
Gemcitabine Hydrochloride
Acute Toxic EffectsIrritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the eye
is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening, or,
occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Section XII.
Ecological Information
Not available.
Ecotoxicity
Environmental FateNot available.
Section XIII. Disposal Considerations

Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
Waste Disposal
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.
Section XIV. Transport Information

DOT ClassificationNot a DOT controlled material (United States).
PIN NumberNot applicable.
Proper Shipping NameNot applicable.
Packing Group (PG)Not applicable.
DOT Pictograms
Section XV. Other Regulatory Information and Pictograms

TSCA Chemical InventoryThis product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS ClassificationNot available.
(Canada)
EINECS Number (EEC) 601-823-3
EEC Risk StatementsR36/37/38- Irritating to eyes, respiratory system and skin.
R60- May impair fertility.
R61- May cause harm to the unborn child.

SECTION 16 - ADDITIONAL INFORMATION

N/A
Toxicological Information
CHEMICAL IDENTIFICATION
RTECS NUMBER :
HA3840000
CHEMICAL NAME :
Cytidine, 2'-deoxy-2',2'-difluoro-, monohydrochloride
CAS REGISTRY NUMBER :
122111-03-9
LAST UPDATED :
199706
DATA ITEMS CITED :
2
MOLECULAR FORMULA :
C9-H11-F2-N3-O4.Cl-H
MOLECULAR WEIGHT :
299.69
HEALTH HAZARD DATA
ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
15 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 48,365,1993
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
15 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 48,365,1993
Safety Information
[ Symbol ]: GHS08
GHS08
[ Signal Word ]: Danger
[ Hazard Statements ]: H360
[ Precautionary Statements ]: P201-P280-P308 + P313
[ Hazard Codes ]: Xi: Irritant;
[ Risk Phrases ]: R21
[ Safety Phrases ]: 25-26-36/37-53
[ RIDADR ]: NONH for all modes of transport
[ HS Code ]: 2934999090
Synthetic RoutePrevious 1/2 Next
Gemcitabine结构式
CAS#:95058-81-4

Gemcitabine

~89%

gemcitabine hydrochloride Structure
CAS#:122111-03-9

gemcitabine hyd...

Literature: Hanmi Pharm. Co.,Ltd Patent: US2007/249818 A1, 2007 ; Location in patent: Page/Page column 10 ;
2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-di benzoate结构式
CAS#:1173824-58-2

2-Deoxy-2,2-dif...

N-trimethylsilyl-N-(2-trimethylsilyloxypyrimidin-4-yl)acetamide结构式
CAS#:18027-23-1

N-trimethylsily...

~51%

gemcitabine hydrochloride Structure
CAS#:122111-03-9

gemcitabine hyd...

Literature: KANNAN, Vishwanath; KASH, Vishwanathan Patent: WO2010/29574 A2, 2010 ; Location in patent: Page/Page column 8-9 ;
2'-deoxy-2',2'-difluorocytidines结构式
CAS#:103882-84-4

2'-deoxy-2',2'-...

~%

4-amino-1-[(2S,4S,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one,hydrochloride结构式
CAS#:122111-05-1

4-amino-1-[(2S,...

gemcitabine hydrochloride Structure
CAS#:122111-03-9

gemcitabine hyd...

Literature: WO2007/117760 A2, ; Page/Page column 21 ;
Precursor & DownStream
Precursor 6 Previous 1/2 Next
Gemcitabine Structure CAS#:95058-81-4
Gemcitabine
2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-di benzoate Structure CAS#:1173824-58-2
2-Deoxy-2,2-dif...
N-trimethylsilyl-N-(2-trimethylsilyloxypyrimidin-4-yl)acetamide Structure CAS#:18027-23-1
N-trimethylsily...
2'-deoxy-2',2'-difluorocytidines Structure CAS#:103882-84-4
2'-deoxy-2',2'-...
DownStream 4
[(2R,5R)-3-benzoyloxy-5-(2,4-dioxopyrimidin-1-yl)-4,4-difluorooxolan-2-yl]methyl benzoate structure CAS#:143157-27-1
[(2R,5R)-3-benz...
Gemcitabine structure CAS#:95058-81-4
Gemcitabine
2',2'-Difluoro-2'-deoxyuridine structure CAS#:114248-23-6
2',2'-Difluoro-...
2'-Deoxy-3',5'-bis-O-[dimethyl(2-methyl-2-propanyl)silyl]-2',2'-d ifluorocytidine structure CAS#:688009-09-8
2'-Deoxy-3',5'-...
Customs
[ HS Code ]: 2934999090
[ Summary ]: 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles27More Articles
Quantitative proteomics of the yeast Hsp70/Hsp90 interactomes during DNA damage reveal chaperone-dependent regulation of ribonucleotide reductase.
J. Proteomics 112 , 285-300, (2015)

The highly conserved molecular chaperones Hsp90 and Hsp70 are indispensible for folding and maturation of a significant fraction of the proteome, including many proteins involved in signal transductio...

Detail
Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer.
Biomaterials 53 , 763-74, (2015)

Multi-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting...

Detail
Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer.
Clin. Cancer Res. 20(24) , 6406-17, (2014)

This study characterized the therapeutic efficacy of a systemically administered formulation of 3-bromopyruvate (3-BrPA), microencapsulated in a complex with β-cyclodextrin (β-CD), using an orthotopic...

Detail
Synonyms
dFdC,Gemzar,Lilly)
MFCD01735988
dFdC Gemzar (Lilly) LY-188011 dFdC dFdCyd
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one hydrochloride
Gemcitabine hydrochloride
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-2(1H)-pyrimidinone hydrochloride
Cytidine, 2'-deoxy-2',2'-difluoro-, hydrochloride (1:1)
2'-Deoxy-2',2'-difluorocytidine hydrochloride (1:1)
Gemcitabine HCl
Gemcitabine HCl(TABINES)